December 10, 2014 @ 1:00 pm – 2:00 pm
Presented by Dr. Jonathan Schuchardt, Partner at Dilworth IP.
About the Presentation
On October 15, 2014, the U.S. Supreme Court heard oral arguments in Teva Pharmaceuticals v. Sandoz, a case that concerns the amount of deference the Federal Circuit must afford a district court’s construction of patent claims.Teva, owner of patents on the multiple sclerosis drug Copaxone®, contends that claim construction is intertwined with fact finding, that Federal Rule of Civil Procedure 52(a) should apply to claim construction, and that a district court’s claim construction should only be set aside for clear error.  In short, the Federal Circuit’s long-standing practice of de novo review of claim construction—which was validated by the Supreme Court’s 1996 decision in Markman v. Westview Instruments and confirmed by the Federal Circuit (6-4) en banc in February 2014 in Lighting Ballast Control v. Philips Electronics—should be overruled.

Sandoz and other generic drug makers counter that Markman remains good law, that Rule 52(a) applies to fact finding outside the context of claim construction, that claim construction is a purely legal matter best left in the hands of a judge rather than a jury, that the current law promotes uniformity and predictability, and that the Federal Circuit correctly reviews claim construction de novo.

Which side will prevail?  Who won the oral argument?  Which justices will reverse their position almost two decades post-Markman?

We’ll review important background decisions, analyze the briefs, dissect the justices’ questions, and speculate about how the Supreme Court will rule.  Join us—it should be “worth the candle”!

About the Presenter

Jonathan L. Schuchardt, Ph.D., J.D., helps scientists, engineers, R&D managers, and business leaders understand complex intellectual property matters so they can protect valuable inventions, avoid conflicts, and innovate with confidence.  Fluent in organic chemistry, catalysis, and polymer chemistry, Jon is an expert in devising patent strategies, growing patent portfolios, and improving IP processes.  Jon is a skillful draftsman, communicator, teacher, and advocate.  Since joining Dilworth IP in 2011, Jon has drafted and prosecuted patent applications, prepared freedom-to-practice opinions, and counseled the firm’s clients on a variety of intellectual property issues.  Previously, Jon was Senior Counsel at LyondellBasell Industries in Newtown Square, PA, where he supported various business areas with patent application drafting, prosecution, counseling, agreement work, transaction support, and client education.  Before transitioning to patent practice, Jon worked for Lyondell’s predecessor ARCO Chemical Company as a research chemist, primarily in the area of polymer synthesis.